Treatment of Candida auris during extracorporeal life support: A case report.
Int J Artif Organs
; 47(3): 223-226, 2024 Mar.
Article
en En
| MEDLINE
| ID: mdl-38281934
ABSTRACT
With rates of ECMO utilization on the rise, prevention of nosocomial infections is of paramount importance. Candida auris, an emerging highly pathogenic multidrug resistant fungus, is of particular concern as it is associated with persistent colonization of environmental surfaces, inability to be recognized by many diagnostic platforms, inconsistent laboratory susceptibility results, and high mortality rates. We describe a case of C. auris in a VV-ECMO patient successfully managed with a combination of anidulafungin, amphotericin B, and flucytosine.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Métodos Terapéuticos y Terapias MTCI:
Plantas_medicinales
Asunto principal:
Candida auris
/
Antifúngicos
Idioma:
En
Revista:
Int J Artif Organs
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos